Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
Status: | Completed |
---|---|
Conditions: | Neurology |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 3 - 21 |
Updated: | 10/20/2018 |
Start Date: | October 2011 |
End Date: | April 2018 |
The purpose of this study is to better understand multiple sclerosis (MS) in children and
adolescents, to learn if it differs from adult MS and to investigate if genes or
environmental exposures or a combination of both put children and adolescents at risk for
getting MS.
adolescents, to learn if it differs from adult MS and to investigate if genes or
environmental exposures or a combination of both put children and adolescents at risk for
getting MS.
The overall goal of this project is to determine whether well-established environmental and
genetic risk factors for adult onset MS play an important role in susceptibility to
pediatric-onset MS. Our study design is based on the hypothesis that genetic influences,
specifically variation at HLA-DRB1 and other confirmed non-MHC MS loci, as well as
environmental exposures including EBV infection and tobacco smoke, contribute to disease
risk. In addition, we will also examine the relationship between serum levels of 25(OH)
vitamin D3 and prior vitamin D status, and risk for pediatric onset MS. Finally, we will
investigate whether specific G x E, and other multivariable relationships influencing risk
exist for pediatric-onset MS. There are 16 collaborating sites other than UCSF that will
enroll cases and controls for this study.
genetic risk factors for adult onset MS play an important role in susceptibility to
pediatric-onset MS. Our study design is based on the hypothesis that genetic influences,
specifically variation at HLA-DRB1 and other confirmed non-MHC MS loci, as well as
environmental exposures including EBV infection and tobacco smoke, contribute to disease
risk. In addition, we will also examine the relationship between serum levels of 25(OH)
vitamin D3 and prior vitamin D status, and risk for pediatric onset MS. Finally, we will
investigate whether specific G x E, and other multivariable relationships influencing risk
exist for pediatric-onset MS. There are 16 collaborating sites other than UCSF that will
enroll cases and controls for this study.
Children are eligible for this study as cases if:
- They have MS or clinically isolated syndrome (CIS):
- MS: As defined by the 2010 McDonald criteria for diagnosis of MS (Polman 2010),
- CIS: A first demyelinating event indicating high risk for MS (i.e., one clinical
event involving the spinal cord, the optic nerve, the brainstem or cerebellum, or
occasionally the hemispheres) and at least 2 silent T2 bright areas on a brain or
spinal cord MRI (at least one must be in the brain); AND
- They are three years of age or older; AND
- Disease onset occurred before 18 years of age.
Patients are not eligible for study participation if:
- Disease onset occurred more than 4 years prior to the opportunity to enroll; OR
- They have had an organ transplant; OR
- They are known to have neuromyelitis optica (NMO).
Children are not eligible to participate as pediatric controls if:
- They are two years of age or younger; OR
- They are 22 years of age or older; OR
- They are known to have MS or another demyelinating disease (for example, neuromyelitis
optica or acute disseminated encephalomyelitis); OR
- They have a biological family member who has been enrolled as a control; OR
- They have an immediate, biological family member (parent/sibling) who has been
diagnosed with MS; OR
- They have an autoimmune disorder (except asthma or eczema); OR
- They have had an organ transplant; OR
- They have a chronic neurological condition with major disability (this does not
include, for example, migraine, controlled seizures, and mild learning disabilities
such as ADD or ADHD).
We found this trial at
17
sites
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Mary Rensel, MD
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Teri Schreiner, MD
Phone: 303-724-6346
Click here to add this to my saved trials
Birmingham, Alabama 35294
Principal Investigator: Jayne Ness, MD
Phone: 205-996-7633
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Tanuja Chitnis, MD
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Mark Gorman, MD
Phone: 857-218-4652
Click here to add this to my saved trials
Buffalo, New York 14203
Principal Investigator: Bianca Weinstock-Guttman, MD
Phone: 716-878-7136
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Jennifer Rubin, MD
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Benjamin Greenberg, MD
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Timothy Lotze, MD
Click here to add this to my saved trials
New York University Langone Medical Center NYU NYU Langone Medical Center, a world-class, patient-centered, integrated,...
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Amy Waldman, MD
Phone: 215-426-8336
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Moses Rodriguez, MD
Phone: 507-266-7196
Click here to add this to my saved trials
Salt Lake City, Utah 84113
Principal Investigator: Meghan Candee, MD
Click here to add this to my saved trials
San Bernardino, California 92408
Principal Investigator: Gregory Aaen, MD
Phone: 909-651-5058
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Emmanuelle Waubant, MD, PhD
Phone: 415-353-1900
Click here to add this to my saved trials
Washington, District of Columbia 20010
Principal Investigator: Ilana Kahn, MD
Click here to add this to my saved trials